Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1972 1
1983 1
1986 2
1987 16
1988 64
1989 64
1990 71
1991 49
1992 62
1993 94
1994 70
1995 73
1996 71
1997 96
1998 83
1999 103
2000 115
2001 104
2002 109
2003 121
2004 135
2005 154
2006 151
2007 154
2008 140
2009 159
2010 186
2011 213
2012 202
2013 262
2014 428
2015 497
2016 555
2017 578
2018 550
2019 557
2020 1193
2021 1345
2022 1216
2023 1060
2024 872
2025 770
2026 103

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,349 results

Results by year

Filters applied: . Clear all
Page 1
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.
Paz-Ares L, Veillon R, Majem M, Zhou C, Tang KJ, Kim SW, Richardson G, Girard N, Sanborn RE, Mansfield AS, Park K, Schuchard J, Diels J, Sermon J, Bhattacharya A, Lorenzini P, Wortman-Vayn H, Knoblauch RE, Agrawal T, Baig M, Ono A, Sabari JK. Paz-Ares L, et al. Lung Cancer. 2026 Mar;213:108788. doi: 10.1016/j.lungcan.2025.108788. Epub 2025 Oct 3. Lung Cancer. 2026. PMID: 41671629 Clinical Trial.
BACKGROUND: Epidermal growth factor receptor (EGFR) exon 20 insertions (Ex20ins) are the third most common type of EGFR mutation, occurring in up to 12% of EGFR-mutated non-small cell lung cancers (NSCLC). Ex20ins-mutated NSCLC can be resistant to most approved tyrosine ki …
BACKGROUND: Epidermal growth factor receptor (EGFR) exon 20 insertions (Ex20ins) are the third most common type of EGFR mutation, occurring …
Cutaneous Histiocytoses.
Rech KL, Collie AM. Rech KL, et al. Surg Pathol Clin. 2026 Mar;19(1):145-161. doi: 10.1016/j.path.2025.09.004. Epub 2025 Oct 23. Surg Pathol Clin. 2026. PMID: 41651609 Review.
Diagnostic performance of monarch robotic bronchoscopy with and without mobile cone-beam CT support.
Chen J, McNierney D, Zein JG, Vaszar LT, Swanson KL, Azadeh N, Sakata KK. Chen J, et al. Lung Cancer. 2026 Mar;213:108910. doi: 10.1016/j.lungcan.2026.108910. Epub 2026 Jan 10. Lung Cancer. 2026. PMID: 41558376
This is the first study to evaluate diagnostic performance between Monarch alone versus Monarch plus mCBCT for peripheral pulmonary lesion (PPL) biopsy, hypothesizing improved DY with the combined approach. METHODS: This single-center retrospective study examined adults un …
This is the first study to evaluate diagnostic performance between Monarch alone versus Monarch plus mCBCT for peripheral pulmonary l …
Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenias of Undetermined Significance: 2026 Update on Clinical Associations and Management Recommendations.
Mangaonkar AA, Bolton KL, Patnaik MM. Mangaonkar AA, et al. Am J Hematol. 2026 Mar;101(3):550-565. doi: 10.1002/ajh.70205. Epub 2026 Jan 8. Am J Hematol. 2026. PMID: 41508691 Review.
CLINICAL ASSOCIATIONS: CH is associated with increased risk for progressive cytopenias (also called clonal cytopenia of undetermined significance), hematological (predominantly myeloid but also lymphoid) neoplasms, cytosis (including monocytosis), and nonhematological conditions …
CLINICAL ASSOCIATIONS: CH is associated with increased risk for progressive cytopenias (also called clonal cytopenia of undetermined signifi …
Shape-sensing robotic-assisted bronchoscopy with integrated mobile cone-beam CT for small nodules: results from the prospective multicentre CONFIRM study.
Husta BC, Cheng GZ, Batra H, Reisenauer JS, Bartek WM, Kalchiem-Dekel O, Zouk A, Patel N, Chawla M, Eapen GA, Jimenez CA, Lee RP, Bott MJ, Oh S, Casal RF. Husta BC, et al. Thorax. 2026 Feb 16;81(3):267-275. doi: 10.1136/thorax-2025-223272. Thorax. 2026. PMID: 41698810
Shape-sensing robotic-assisted bronchoscopy (ssRAB) integrated with mCBCT has been introduced to correct for CT to body divergence (CT-BD) during the biopsy of peripheral pulmonary nodules (PPNs). METHODS: Prospective observational multicentre study, enrolling patients wit …
Shape-sensing robotic-assisted bronchoscopy (ssRAB) integrated with mCBCT has been introduced to correct for CT to body divergence (CT-BD) d …
Prevalence and trajectories of post-COVID-19 neuromuscular conditions: A systematic-review and meta-analysis.
Pupillo E, Leone MA, Amato A, Bianchi E, Damian MS, Dyck J, Garcia-Azorin D, Giussani G, Guekht A, Koike H, Khadilkar S, Lehmann H, Pochigaeva K, Povolnova J, Tumurov D, Vetrov F, de Visser M, Winkler AS, Grisold W. Pupillo E, et al. J Neurol Sci. 2026 Feb 15;481:125710. doi: 10.1016/j.jns.2025.125710. Epub 2025 Dec 25. J Neurol Sci. 2026. PMID: 41494305 Review.
INTRODUCTION: Neuromuscular diseases (NMDs) are a significant component of the post-acute sequelae of COVID-19. However, their long-term prevalence and trajectories remain poorly defined. This systematic review and meta-analysis aimed to determine the long-term prevalence …
INTRODUCTION: Neuromuscular diseases (NMDs) are a significant component of the post-acute sequelae of COVID-19. However, their long-t …
Association of Type III and Type VI Collagen Neoepitopes With Disease Severity in Systemic Sclerosis.
Ayla AY, Bernstein EJ, Zhang M, VanBuren JM, Castelino FV, Chung L, Evnin L, Frech TM, Gordon JK, Hant FN, Hummers LK, Khanna D, Lakin KS, Lebiedz-Odrobina D, Luo Y, Makol A, Mayes M, McMahan ZH, Molitor JA, Moore DF, Richardson C, Sandorfi N, Shah AA, Shah A, Shanmugam VK, Skaug B, Steen VD, Volkmann ER, Zahn C, Zheng WJ, Assassi S. Ayla AY, et al. J Rheumatol. 2026 Feb 15:jrheum.2025-0532. doi: 10.3899/jrheum.2025-0532. Online ahead of print. J Rheumatol. 2026. PMID: 41241390 Free PMC article.

PRO-C3 (P < 0.001) and PRO-C6 (P < 0.001) concentrations were higher in patients with diffuse disease, whereas C6M (P = 0.04) was higher in those with interstitial lung disease. Baseline PRO-C3 (P < 0.001) and PRO-C6 (P < 0.001) positively correlated with mRSS,

…

PRO-C3 (P < 0.001) and PRO-C6 (P < 0.001) concentrations were higher in patients with diffuse disease, whereas C6M (P = 0.04) was high

…
11,349 results
You have reached the last available page of results. Please see the User Guide for more information.